Press coverage about G1 Therapeutics (NASDAQ:GTHX) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. G1 Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5038038124439 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- G1 Therapeutics Announces Closing of Offering of Common Stock (finance.yahoo.com)
- G1 Therapeutics (GTHX) Upgraded to Buy at BidaskClub (americanbankingnews.com)
- Wedbush Equities Analysts Decrease Earnings Estimates for G1 Therapeutics Inc (GTHX) (americanbankingnews.com)
- G1 Therapeutics (GTHX) Given “Buy” Rating at BTIG Research (americanbankingnews.com)
- G1 Therapeutics (GTHX) Commences 3M Share Offering of Common Stock (streetinsider.com)
GTHX has been the topic of several recent analyst reports. BTIG Research initiated coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 target price on the stock. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. JPMorgan Chase & Co. increased their target price on G1 Therapeutics to $30.00 in a research report on Monday, February 5th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Monday, March 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $36.60.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). research analysts predict that G1 Therapeutics will post -2.47 EPS for the current year.
In other news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $19.75, for a total value of $3,950,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $20.00, for a total value of $75,520.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 217,302 shares of company stock worth $4,314,417.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/03/13/g1-therapeutics-gthx-earns-news-impact-rating-of-0-17/2022008.html.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.